# US 2012/0252892 A1 · Methods for treating fibromyalgia syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252892 A1
- Document ID: US20120252892A1
- Status: Published application
- Kind: A1
- Application number: 13/508,145
- Filed: 2010-11-01
- Published: 2012-10-04
- Earliest claimed: 2009-11-06
- Assignees: SK Biopharmaceuticals Co., Ltd.
- Inventors: Sung James Lee; Susan Marie Melnick
- Web page: https://patentgrep.com/patent/US20120252892A1

## CPC

- C07C 271/08: having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/223: of alpha-aminoacids
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/24: Antidepressants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method of treating fibromyalgia syndrome comprising the administration of a therapeutically effective amount of a compound having structural Formula (1) or a pharmaceutically acceptable salt thereof, to a mammal in need of treatment:
wherein,
R is selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy of 1 to 3 carbon atoms, nitro group, hydroxy, trifluoromethyl, and thioalkoxy of 1 to 3 carbon atoms;
x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3;
R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms;
R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the heterocyclic compound comprises 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, and the nitrogen atoms are not directly connected with each other or with the oxygen atom.

### Claim 2 (depends on 1)

The method of claim 1 wherein R is hydrogen and x=1.

### Claim 3 (depends on 1)

The method of claim 1 wherein R, R1 and R2 are hydrogen and x=1.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound having structural Formula (1) is an enantiomer substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of the compound having structural Formula (1) predominates.

### Claim 5 (depends on 4)

The method of claim 4, wherein one enantiomer predominates to the extent of about 90% or greater.

### Claim 6 (depends on 5)

The method of claim 5, wherein one enantiomer predominates to the extent of about 98% or greater.

### Claim 7 (depends on 4)

The method of claim 4, wherein the enantiomer is (S) or (L) enantiomer as represented by Structural Formula (1a):
wherein, R, x, R1 and R2 are as previously defined.

### Claim 8 (depends on 7)

The method of claim 7, wherein one enantiomer predominates to the extent of about 90% or greater.

### Claim 9 (depends on 8)

The method of claim 8, wherein one enantiomer predominates to the extent of about 98% or greater.

### Claim 10 (depends on 7)

The method of claim 7, wherein Rx, R1 and R2 are hydrogen and x is 1.

### Claim 11 (depends on 4)

The method of claim 4, wherein the enantiomer is (R) or (D) enantiomer, as represented by Structural Formula (1b).
wherein, R, x, R1 and R2 are as previously defined.

### Claim 12 (depends on 11)

The method of claim 11, wherein one enantiomer predominates to the extent of about 90% or greater.

### Claim 13 (depends on 12)

The method of claim 12, wherein one enantiomer predominates to the extent of about 98% or greater.

### Claim 14 (depends on 11)

The method of claim 11, wherein the enantiomer is (R)-(beta-amino-benzenepropyl)carbamate.

### Claim 15 (depends on 14)

The method of claim 14, wherein the enantiomer of (R)-(beta-amino-benzenepropyl)carbamate predominates to the extent of about 90% or greater.

### Claim 16 (depends on 15)

The method of claim 15, wherein the enantiomer of (R)-(beta-amino-benzenepropyl)carbamate predominates to the extent of about 98% or greater.

### Claim 17

A pharmaceutical composition for treating fibromyalgia syndrome comprising the administration of a therapeutically effective amount of a compound having structural Formula (1) or a pharmaceutically acceptable salt thereof, to a mammal suffering from fibromyalgia:
wherein,
R is selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy of 1 to 3 carbon atoms, nitro group, hydroxy, trifluoromethyl, and thioalkoxy of 1 to 3 carbon atoms;
x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3;
R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms;
R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the heterocyclic compound comprises 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, and the nitrogen atoms are not directly connected with each other or with the oxygen atom.
